Oxford BioDynamics (GB:OBD) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Oxford BioDynamics Plc has reported continued growth in its biotechnology segment with an emphasis on the commercialization of its EpiSwitch tests, observing a revenue increase and expanding market presence through various commercial agreements. Despite an operating loss, the company has successfully secured funding to support near-term plans and has advanced its test offerings, including securing US reimbursement for its EpiSwitch PSE test and partnering with health providers for broader access.
For further insights into GB:OBD stock, check out TipRanks’ Stock Analysis page.